ArticleClinical and translational science2026
Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics (PGx) applies knowledge of drug-gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT-GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non-White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge (β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female (β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self-reported health literacy (β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns (β = -3.7, 95% CI [-5.8, -1.7], p < 0.001) or did not complete secondary education (β = -2.0, 95% CI [-3.5, -0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient-informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research-engaged and from a single institution, the study population may not be widely generalizable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.